Oncogenic Ras-induced macropinocytosis: A new paradigm for metabolic adaptation

致癌 Ras 诱导的巨胞饮作用:代谢适应的新范例

基本信息

  • 批准号:
    9348606
  • 负责人:
  • 金额:
    $ 99.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-09-07 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

Tumors harboring oncogenic Ras mutations are notoriously resistant to existing targeted therapies. This grave reality coupled with the fact that Ras mutations are prevalent in some of the deadliest cancers underscore the urgent need to identify new targeting strategies that can be translated to effective therapies for Ras-driven tumors. The overarching goal of this research program is to address this need by capitalizing on the emerging paradigm that the metabolic rewiring of Ras tumor cells constitutes a core vulnerability that can be exploited therapeutically. Specifically, we will pursue a novel nutrient delivery mechanism that was recently elucidated in my laboratory and is rooted in a discovery I made earlier in my career that oncogenic Ras stimulates a fluid-phase endocytic process known as macropinocytosis (MP). We recently discovered that this process is exploited by mutant Ras cells to internalize extracellular protein and deliver it to where it is degraded to generate free amino acids that can fuel metabolic pathways. Our studies to date strongly indicate that understanding the molecular underpinnings of this process and defining its pathophysiological consequences hold promise for defining new intervention approaches for mutant Ras tumors. We propose to rigorously test this idea by pursuing three broad questions: 1) How does oncogenic Ras regulate MP? 2) What are the functional consequences of oncogenic-Ras mediated MP?, and 3) Can MP be exploited as a therapeutic target? We are uniquely positioned to address these questions owing to the progress we have made thus far and our access to relevant expertise. We anticipate that this research program will yield new insights into Ras-dependent oncogenic mechanisms of translational relevance. .
众所周知,携带致癌Ras突变的肿瘤对现有的靶向药物具有耐药性 治疗这一严重的现实,加上Ras突变在一些人中普遍存在的事实, 最致命的癌症强调迫切需要确定新的靶向战略, 对于Ras驱动的肿瘤的有效疗法。这项研究计划的首要目标是 通过利用新兴的范式来满足这一需求,即Ras肿瘤的代谢重新布线 细胞构成了一个核心弱点,可以在治疗上加以利用。具体而言,我们将继续 一种新的营养输送机制,最近在我的实验室里被阐明, 我在职业生涯早期发现致癌Ras刺激液相内吞过程 称为巨胞饮(MP)。我们最近发现这个过程被突变的Ras 细胞内化胞外蛋白并将其递送到降解产生游离氨基的地方 能为代谢途径提供燃料的酸。我们迄今为止的研究强烈表明, 这一过程的分子基础和定义其病理生理后果 为突变型Ras肿瘤定义新的干预方法的承诺。我们建议严格 通过以下三个广泛的问题来验证这个观点:1)致癌Ras如何调节MP?2)是什么 致癌Ras介导的MP?的功能后果,3)MP是否可以作为一种 治疗目标?由于我们取得的进展, 以及我们获得相关专业知识的途径。我们预计,这项研究计划将 产生新的见解Ras依赖致癌机制的翻译相关性。 .

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAFNA BAR-SAGI其他文献

DAFNA BAR-SAGI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAFNA BAR-SAGI', 18)}}的其他基金

A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.
一种治疗突变型 KRas 胰腺癌的新型单体药物缀合物。
  • 批准号:
    10666997
  • 财政年份:
    2022
  • 资助金额:
    $ 99.32万
  • 项目类别:
A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.
一种治疗突变型 KRas 胰腺癌的新型单体药物缀合物。
  • 批准号:
    10323748
  • 财政年份:
    2021
  • 资助金额:
    $ 99.32万
  • 项目类别:
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma
一种治疗突变 Ras 多发性骨髓瘤的新型单体药物偶联物
  • 批准号:
    10080987
  • 财政年份:
    2020
  • 资助金额:
    $ 99.32万
  • 项目类别:
Dectin-1 signaling drives pancreatic oncogenesis by inducing macrophage-mediated adaptive immune suppression
Dectin-1 信号传导通过诱导巨噬细胞介导的适应性免疫抑制来驱动胰腺肿瘤发生
  • 批准号:
    10359672
  • 财政年份:
    2017
  • 资助金额:
    $ 99.32万
  • 项目类别:
Dectin-1 signaling drives pancreatic oncogenesis by inducing macrophage-mediated adaptive immune suppression
Dectin-1 信号传导通过诱导巨噬细胞介导的适应性免疫抑制来驱动胰腺肿瘤发生
  • 批准号:
    10054171
  • 财政年份:
    2017
  • 资助金额:
    $ 99.32万
  • 项目类别:
Oncogenic Ras-induced macropinocytosis: A new paradigm for metabolic adaptation
致癌 Ras 诱导的巨胞饮作用:代谢适应的新范例
  • 批准号:
    10208796
  • 财政年份:
    2016
  • 资助金额:
    $ 99.32万
  • 项目类别:
Oncogenic Ras-induced macropinocytosis: A new paradigm for metabolic adaptation
致癌 Ras 诱导的巨胞饮作用:代谢适应的新范例
  • 批准号:
    9979778
  • 财政年份:
    2016
  • 资助金额:
    $ 99.32万
  • 项目类别:
Oncogenic Ras-induced macropinocytosis: A new paradigm for metabolic adaptation
致癌 Ras 诱导的巨胞饮作用:代谢适应的新范例
  • 批准号:
    10430204
  • 财政年份:
    2016
  • 资助金额:
    $ 99.32万
  • 项目类别:
Oncogenic Ras-induced macropinocytosis: A new paradigm for metabolic adaptation
致癌 Ras 诱导的巨胞饮作用:代谢适应的新范例
  • 批准号:
    9190721
  • 财政年份:
    2016
  • 资助金额:
    $ 99.32万
  • 项目类别:
Research Training for Physician-Scientists in Gastrointestinal Oncology
胃肠肿瘤学医师科学家研究培训
  • 批准号:
    10478062
  • 财政年份:
    2015
  • 资助金额:
    $ 99.32万
  • 项目类别:

相似海外基金

Chemical evolution of synthetic bacterial cells by reprograming protein translation with non-canonical amino acids
通过使用非规范氨基酸重新编程蛋白质翻译来合成细菌细胞的化学进化
  • 批准号:
    RGPIN-2020-05669
  • 财政年份:
    2022
  • 资助金额:
    $ 99.32万
  • 项目类别:
    Discovery Grants Program - Individual
Chemical evolution of synthetic bacterial cells by reprograming protein translation with non-canonical amino acids
通过使用非规范氨基酸重新编程蛋白质翻译来合成细菌细胞的化学进化
  • 批准号:
    RGPIN-2020-05669
  • 财政年份:
    2021
  • 资助金额:
    $ 99.32万
  • 项目类别:
    Discovery Grants Program - Individual
Chemical evolution of synthetic bacterial cells by reprograming protein translation with non-canonical amino acids
通过使用非规范氨基酸重新编程蛋白质翻译来合成细菌细胞的化学进化
  • 批准号:
    RGPIN-2020-05669
  • 财政年份:
    2020
  • 资助金额:
    $ 99.32万
  • 项目类别:
    Discovery Grants Program - Individual
Novel logic gates in mammalian cells based on genetically incorporated unnatural amino acids
哺乳动物细胞中基于基因掺入的非天然氨基酸的新型逻辑门
  • 批准号:
    EP/T020687/1
  • 财政年份:
    2020
  • 资助金额:
    $ 99.32万
  • 项目类别:
    Research Grant
Tolerance of cancer cells against amino acids deprivation in tumor microenvironments
癌细胞对肿瘤微环境中氨基酸剥夺的耐受性
  • 批准号:
    19H03496
  • 财政年份:
    2019
  • 资助金额:
    $ 99.32万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Analysis of metabolic remodeling in amino acids in glioblastoma cells
胶质母细胞瘤细胞氨基酸代谢重塑分析
  • 批准号:
    17K16648
  • 财政年份:
    2017
  • 资助金额:
    $ 99.32万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Maintenance of undifferentiated state of mesenchymal stem cells using amino acids for the regulation of stem cell aging
使用氨基酸维持间充质干细胞的未分化状态以调节干细胞衰老
  • 批准号:
    15K15708
  • 财政年份:
    2015
  • 资助金额:
    $ 99.32万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Amino acids and regulation of protein synthesis in muscle cells
肌肉细胞中的氨基酸和蛋白质合成的调节
  • 批准号:
    416205-2011
  • 财政年份:
    2011
  • 资助金额:
    $ 99.32万
  • 项目类别:
    University Undergraduate Student Research Awards
Expressing unnatural fluorescent amino acids in eukaryotic cells
在真核细胞中表达非天然荧光氨基酸
  • 批准号:
    399819-2010
  • 财政年份:
    2010
  • 资助金额:
    $ 99.32万
  • 项目类别:
    University Undergraduate Student Research Awards
The study of amino acids imbalance which influences the immune cells, especially dendritic cells, in patients with advanced cirrhosis.
研究氨基酸失衡对晚期肝硬化患者免疫细胞,特别是树突状细胞的影响。
  • 批准号:
    21790643
  • 财政年份:
    2009
  • 资助金额:
    $ 99.32万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了